In lung cancer, elevated levels of miR-200c-3p, miR-21-5p, and miR-28-5p have been reported in pre-treatment plasma EVs from advanced NSCLC patients who did not respond to anti-PD1 or anti-PDL1 therapy [284]. The gene discussed is CD274; the disease is lung cancer.